TARRGET Pilot Study – Research Update

The Targeting At Risk Relatives of Glaucoma patients for Early diagnosis and Treatment (TARRGET) study is a partnership project between Glaucoma Australia and the Australian and New Zealand Registry of Advanced Glaucoma (ANZRAG), based at Flinders University, Adelaide.

TARRGET aimed to investigate the feasibility of offering free glaucoma screening to immediate relatives of people who have been diagnosed with advanced glaucoma. Researchers hypothesised that relatives of those people severely affected by glaucoma would have higher rates of glaucoma diagnosis than relatives of less severely affected glaucoma patients.

The pilot study has revealed that if you have advanced glaucoma your first degree relatives have up to a 54% chance of developing the disease, which is simply staggering.

Here we have summarised some of the key findings:

- The pilot study recruited 177 first degree relatives, with 131 completing the eye examination.
- 72 of the 131 first degree relatives screened either had glaucoma or had early signs that need to be monitored carefully.
- This indicates that if a person has a family member with advanced glaucoma they have up to a 54% chance of developing the disease.
- 93% of participants were aware of their family history, however 17% stated they had not been screened for glaucoma before, with an additional 14% having had an eye health check but unsure if they had been screened for glaucoma.
- One third of first degree relatives did not understand how their family history of glaucoma related to their own personal risk of developing glaucoma.
- Newly detected cases of glaucoma tended to have intra-ocular pressure in the normal tension range, mild visual field defects and cup-to-disc ratio below 0.7 with a similar trend found in new suspects.

As the project transforms to a national study, we will look to advocate for better screening pathways for these individuals. This may involve lobbying for altered Medicare structures for nerve fibre layer testing and ongoing screening of family members. An important part of this process has been to realise that family members often feel that after one “normal” test they are cleared of the risk of glaucoma. In fact, as an ageing disease, ongoing, lifetime monitoring is required at least every 2 years.

If you have glaucoma – one way you can help reduce vision loss from glaucoma is to make sure your first degree relatives understand that they are also at risk and should have a regular eye exam.

To read the full report visit www.glaucoma.org.au/news/research-articles
Dear Friends and Supporters

The past three months have been a hive of activity at Glaucoma Australia as we continue with our vital mission to boost the detection of glaucoma.

Our team led by CEO Annie Gibbins have been very busy developing and trialing a new patient support journey to ensure every person diagnosed with glaucoma is actively being supported by Glaucoma Australia through personalised education and support when they need it most.

A recent trial of the new patient support journey with 200 patients recently referred to us has indicated where intervention and education is most required. Ideally, contact from Glaucoma Australia pre and post consultation and at 5 months post diagnosis, is aimed at increasing appointment and treatment adherence rates. Strategic interventions, both by phone and email, are now targeted toward improving education and support from the point of diagnosis and throughout the patient journey. Very importantly, we encourage people with glaucoma to alert their family members to the risk they also face and the urgent need to have a check for glaucoma.

We’re confident that this ground-breaking work will impact early detection rates, patient knowledge, reduce anxiety and improve treatment participation.

New Resources

In addition, new patient centered support resources are being developed and are now mapped to the four specific stages of the patient journey – diagnosis, starting treatment, adherence and ongoing management.

Some of our new resources include:
- Glaucoma Risk Calculator – assess your potential risk of developing glaucoma based on age, gender, ethnicity, family history of glaucoma and other health issues such as diabetes and myopia.
- Glaucoma in Perspective – watch glaucoma in action in a series of videos.
- How to prepare for your ophthalmic appointment – including a list of questions you might like to ask your specialist.

Visit www.glaucoma.org.au/resources to access new and existing resources.

Glaucoma Research: A Year of Progress

As custom dictates, the July issue of Glaucoma News is dedicated to glaucoma research and the achievements and progress made over the past year. I’d like to thank Dr Simon Skalicky & Clinical Associate Professor Andrew White for providing a very comprehensive year in review. I am pleased to see progress and activity in many areas of glaucoma research, which will ultimately provide better care and outcomes for people with glaucoma.

In addition we have recently received the latest report on the TARGRET Pilot Study and the results are staggering. If you have advanced glaucoma your first degree relatives have up to a 54% chance of developing the disease. I encourage everyone to read the summary of results on page 1.

Glaucoma Australia Research Framework

Over the past 6 months, your Council has formulated a long-term research strategy for the next 5 – 10 years to ensure research funding is directed towards projects that will create a more hopeful future for people with glaucoma.

As part of this strategic process we have identified four research domains that centre on the practical challenges of managing glaucoma by:
- Improving the treatment experience for people with glaucoma.
- Improving the quality and experience of monitoring the condition progression for individual people and maintaining better population wide statistics.
- Increasing the rate and reliability of detection. That is, detect more people earlier in their progression.
- Providing management tools to improve the quality of life for people with glaucoma.

I am pleased to advise you that Glaucoma Australia will soon be seeking expressions of interest from leading research organisations interested in collaborating with Glaucoma Australia to fund research projects that deliver on these research domains and our mission: to eliminate glaucoma.

Kathleen Holmes Scholarships

Congratulations to the following young doctors on being awarded a 2018 Glaucoma Australia ‘Kathleen Holmes’ Scholarship: Ellie Bowditch, Lukas Sahhar, Kay Lam and Joobin Hoshmand.

Miss Kathleen Holmes was the co-founder of Glaucoma Australia 30 years ago and was awarded an OAM in 1996 in recognition of her dedication to the glaucoma cause.

These scholarships enable ophthalmology trainees to attend the annual Australian and New Zealand Glaucoma Society (ANZGS) Scientific Meeting. We hope the $1125 you receive can be used to progress your knowledge and skill development in the fight against glaucoma blindness.

It was a delight for Glaucoma Australia CEO Annie Gibbins to meet Mr Marcus Quinlivan OAM in Canberra recently.

Mr Quinlivan is the founder of The William A Quinlivan – Glaucoma Australia Research and Scholarship Fund, set up in memory of his late father. Mr Quinlivan proposed and financed the establishment of this special fund with the cooperation of Glaucoma Australia to fund research into glaucoma including its causes, treatments and eventual cure.

The TARGRET study has been an excellent example of how genetic research can influence future campaigns aimed at finding the 50% of people currently undiagnosed with glaucoma. Data from this research indicates that first degree relatives of people with advanced glaucoma appear to have a higher than 54% chance of developing the disease. I have therefore recently received the summary of results on page 1.

Glaucoma Australia Research Framework

Further research is now being planned for more social research which will improve communications that influence behavioural changes related to early detection and treatment adherence.

Our focus is to take glaucoma seriously and act at the earliest opportunity.

If you would like to donate to the William A Quinlivan – Glaucoma Australia Research and Scholarship Fund please call 02 9411 7722.

Sydney resident Bob Corben shares his glaucoma story.

I had no idea I had glaucoma until I changed optometrist in 2001. That very observant man did a regular eye examination and discovered a problem there and immediately referred me to an ophthalmologist.

When I was first diagnosed with glaucoma I really didn’t have a clue what it was all about. I thought oh well it’s another problem to deal with in life. I really underestimated what glaucoma was all about. Now I find glaucoma is one of the most frightening diseases I could ever know about – but it’s not going to win in my case. I’m very positive about the way I’m facing it and the way it’s being treated by the best people I know. I have a great specialist who I visit every three months.

I would have been about 52 or 53 when I was first diagnosed with glaucoma. Interestingly enough my ophthalmologist told me if I had gone another 5 or 6 years I’d probably be blind by now.

I couldn’t picture being blind, just the thought of it is frightening. So I do everything I possibly can to look after my eyes. My glaucoma is in an advanced stage – but I still have very good eyesight in both eyes and I have an unrestricted driving license.

My dear Mum had glaucoma. I knew that she had glaucoma when I was a teenager, but I didn’t know it was hereditary. I was never told it could be passed on by my ophthalmologist or anyone else for that matter; or my mum, she wasn’t aware of it either. I just wish there would have been a greater education about glaucoma and its effects then, as there is now.

I have a brother and two sisters, and I make sure they get tested for glaucoma regularly. Thankfully none of them have been found to have glaucoma and neither have my children, but they all get checked regularly.

I urge people to get tested for glaucoma. When you go for your next regular eye test ask specifically for a test for glaucoma. It’s a hidden disease, so you don’t know if you’ve got it, and if there is a history in the family please get tested very quickly.

© No part of Glaucoma News, published by Glaucoma Australia Inc., may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the written permission of the copyright owner.
Greater knowledge of disease risk factors, new approaches to detection and monitoring, and innovative treatments are positively impacting glaucoma outcomes. Over the past year we’ve seen a continued shift towards surgical/laser management of glaucoma, coupled with depot preparation medication trials rather than drop therapy. A major prospective trial looking at the efficacy of depot bimatoprost intracamerally has just finished recruiting (ARTEMIS 2 and ATHENA). Other similar trials are underway as well as assessment of an ocular ring releasing bimatoprost.1,2

Minimally Invasive Glaucoma Surgery

Undoubtedly in 2017, glaucoma clinical practice focused on minimally invasive glaucoma surgery (MIGS). MIGS represents a broad group of small surgical devices characterised by minimal conjunctival dissection, short operating times, rapid recovery and a good safety profile. This is a rapidly expanding field with trans-trabecular devices (eg iStent, Glaukos), increasingly performed in conjunction with cataract surgery.

Other devices are available, with a growing body of supportive data, such as the Cypass (Alcon), which creates a cyclodialysis cleft and drains to the suprachoroidal space and the Hydrus microstent (Ivantis), a fenestrated curved tube that enters, passes through and dilates Schlemm’s canal.

Currently, Medicare restricts the use of these devices to only at the time of cataract surgery, although work is underway to expand the availability for the procedure to a wider body of glaucoma patients, and potentially allow stand-alone MIGS procedures.

There is still a scarcity of robust MIGS scientific data. A meta-analysis of all MIGS papers released up until 2016 found that while overall safety data from MIGS is reassuring, good head-to-head random clinical trials comparing MIGS devices to one another or to traditional glaucoma surgery is lacking.2,5 As clinicians in this field, it is imperative we collect quality local data that evaluates MIGS in real-world clinical practice, and audit through communal software platforms such as the Save Sight Registry.

Hydrus was compared head-to-head with selective laser trabeculoplasty (SLT) in a small (n=56) case series. Hydrus resulted in a greater reduction in medication dependence than SLT at 12 months.5

Laser Trabeculoplasty

Glaucoma filtration surgery (eg. trabeculectomy, tube surgery) involves creating an aqueous drainage pathway from inside the eye to the subconjunctival space. Some preliminary results have been released for the Primary Trab vs. Tube Study (PTTV) that attempts to settle the question as to whether a primary drainage tube may be better than trabeculectomy as a first surgical procedure for glaucoma. In a word, no.7,8 IOP control was better in the trabeculectomy group, especially in those with lower starting IOP. The complication rate was similar despite more early complications/interventions in the trabeculectomy group.

The Xen Gel Implant (Allergan) is a soft collagen implant that is inserted, ab interno, from the anterior chamber into the subconjunctival space creating a bleb. In many ways it is more similar to traditional filtration surgery than other MIGS devices. It is increasingly used as an alternative to trabeculectomy, although quality head-to-head studies comparing Xen to trabeculectomy are few.

The Xen was shown to be effective in uveitic glaucoma, despite the potential for sight-threatening complications of hypotony, bleb infection9 or suprachoroidal haemorrhage10 (ie similar complications to a trabeculectomy).

Lithotripsy

Lithotripsy is a form of extracorporeal shockwave therapy. It generates extremely high pressure pulses from high intensity shockwaves, which can be directed at various disease targets.

The frequency of monitoring for glaucoma patients continues to vex strained clinics. One study found twice yearly visual field testing had similar sensitivity to thrice yearly for detecting glaucoma progression, provided two quality baseline tests were available for reference.28
progressors were older, had significantly lower baseline for rapid glaucoma progression showed rapid OCT metrics (RNFL and MGC complex thickness).33 Additionally, a retrospective study looking at risk factors than a single gene that is causative?). Stay tuned.

The Genetics of Glaucoma

The last few years have seen an explosion of genes identified in glaucoma pathogenesis. Novel loci include: for POAG (ABCA1, AFAF1, GMDS, PMM2, TGFB3, FNDCC3, ARHGEP2, GAS7, FOXC1, AXTN2, TXNRD2); PACG (EPDP1, CHAT, GLIS3, FERM1T2, DPM2-FAM102); and pseudoexfoliation syndrome glaucoma (CACNA1A).37 There are so many genes implicated that work is beginning to move towards better phenotyping of glaucoma for targeted gene studies, and studies looking at the functionality of these genes and interactions with each other (i.e. is it combinations of gene anomalies rather than a single gene that is causative?). Stay tuned.

Health, Socioeconomic and Lifestyle Factors

Smoking was the smoking gun for glaucoma in 2017. A Spanish cohort population study of 18,797 participants over 8.5 years demonstrated a direct association between current smokers and glaucoma incidence, and the risk increased with number of pack-years.34

Additionally, a retrospective study looking at risk factors for rapid glaucoma progression showed rapid progressors were older, had significantly lower baseline IOP and central corneal thickness, and significantly higher rates of cardiovascular disease and hypotension.35

References supplied.

Further prospective study needs to be done to better understand the pathophysiology behind this finding.

A Taiwanese study evaluated the influence of different socioeconomic factors on vision-related quality of life in glaucoma. A lower education – but not income – affected QoL, detrimentally, suggesting the importance of additional counselling for patients with a lower educational level to help them cope with the disease.36

“there seems to be an increasing role for dietary and nutritional supplementation in preventing glaucoma and/or halting progression”

Other Medical Therapies

Drug development for new glaucoma therapies has been slow but continues.

Rhopressa (Netarsudil 0.02 per cent) is a once daily topical agent with two mechanisms of action and two targets. Rhopressa targets rho-kinase (ROCK) and a norepinephrine transporter (NET). Trial results (ROCKET1-4) yet to be published seem promising. The most common side effect was mild redness of the eyes.

A combination product, Roclatan, is a once daily, combination of netarsudil 0.02 per cent + latanoprost 0.005 per cent made by the same company (Aerie Pharmaceuticals). Initial results from two trials (Mercury 1 and 2) also seem promising.

A new pathway for treatment was discovered this year that may also show promise. The angiopoietin-Tie2 pathway is crucial in the development and maintenance of Schlemm’s canal and hence IOP control. Antibody mediated activation of Tie2 resulted in an increase in drainage apparatus in Schlemm’s canal when injected in mice. Further development of this pathway may lead to a new IOP lowering agent in the future.

Conclusion

As clinical and laboratory science marches forward, we must stay nimble in our approach to clinical practice, and translate the new knowledge into better, more efficient and more inclusive glaucoma care delivery to all patients.

This article first appeared in mivision issue 132 March 2018. It has been reprinted with the permission of mivision (Toma Publishing)

Giving Hope

By leaving a charitable bequest to Glaucoma Australia you are giving hope to future generations.

We know that most forms of glaucoma are hereditary. Your generosity will help improve glaucoma awareness, detection, treatment and support for families at risk as well as helping to fund valuable research.

If you would like to become a GIVER OF HOPE please call Annie Gibbons on 02 9411 7722 or email ceo@glaucoma.org.au

GIVING HOPE

Many thanks to the companies, clubs and organisations who provided financial and other support to Glaucoma Australia:

Platinum
- Marcus Quinlivan OAM

Gold
- Carr Family Trust

Silver
- Novartis

Bronze
- Allergan
- Pfizer

Supporters
- Alcon
- Anonymous
- Glaukos
- Evolvehope Family Trust
- Icare
- Mundipharma
- Perpetual
- Specsavers
- The Angles Family Foundation

Media Supporters
- Insight Magazine
- mivision Magazine
- Today’s Ophthalmic News

Allied Partners
- Brien Holden Vision Institute
- MedAdvisor
- Oculo
- Optometry Australia
- Orthoptics Australia
- RANZCO
- Vision2020

Bequests 2018
- The estate of the Late Dorothea Watt
- The estate of the Late Eileen Doris Gabriel
- The estate of the Late Isabel Mary Tangie
- The estate of the Late Eileen Merle Masters
- The estate of the Late Katherine Mander
We recently filmed a series of videos with orthoptist and Glaucoma Australia educator Jan Howlett to answer some of your more frequently asked questions. You can watch these videos on YouTube www.youtube.com/GlaucomaAustralia or read the questions and answers below.

**Does surgery improve my vision?**
Glaucoma surgery, like all other glaucoma treatment options, aims to reduce the risk of any further vision loss but is unable to give back vision already lost from glaucoma. Vision loss through glaucoma is permanent.

**How does the eye specialist determine my follow-up time?**
Eye health follow-ups fall into two categories:
1. for patients with glaucoma; and
2. for patients who are at risk of developing glaucoma.

The time between appointments for both categories is determined by a complex combination of factors, which include, but are not limited to:
- whether you have a family member with glaucoma,
- your health status
- your age, and
- the medications you take.

For those with glaucoma additional factors are considered:
- the degree of your optic nerve damage and the visual field loss.
- how recently your diagnosis was made
- how recently you started or changed treatment

So at your initial and all subsequent appointments, your eye specialist will determine when your eyes need to be checked again based on this data.

**Why should I keep taking my eye drops?**
Glaucoma can’t be cured. The aim of all glaucoma treatment is to prevent any further vision loss from the disease.

Eye drops are prescribed to reduce your eye pressure. When your eye pressure is too high, it damages the optic nerve which in turn causes irreparable damage to your vision. So if you have been prescribed eye drops it is very important to keep using them exactly in the manner your eye care professional has prescribed.

If you stop using the prescribed eye drops, the pressure in your eye will go up again and the damage to the optic nerve and your vision will restart.

Always tell your eye care professional if you are having trouble using your eye drops and your treatment will be adjusted accordingly to address your problems.

**Why do I need a visual field test?**
A glaucoma diagnosis is based on evidence of optic nerve damage and/or visual field loss. However, visual field damage will not be obvious to you during your daily activities because firstly this initial glaucoma damage affects the very extremities of eyesight and second because we turn our head to view objects to our far right or left, up or down, such vision field loss is rarely noticed.

The automated visual field test accurately maps out your field of vision one eye at a time. This shows the level of function of the millions of vision fibres that give you sight. Any damage to either eye’s vision fibres will show up in this test. At your initial consultation, this test, when abnormal, indicates a likely glaucoma diagnosis. The optic nerve and any damage is reviewed in conjunction with this visual field test result. Together they are the evidence your eye care professional relies on to determine whether you have glaucoma or not. Subsequent visual field tests monitor treatment efficacy.

Once glaucoma is confirmed, treatment is started immediately to prevent any further vision loss. This visual field test needs to be performed regularly to check that treatment is adequate. If this automated field test shows further vision loss is occurring, your treatment is adjusted accordingly until such time that there are no longer any signs of ongoing damage and vision loss.